Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc. · Metrics

Track ABCL — free

Use ABCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.62 -0.33 (-2.76%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$3.80B
Shares
326.62M
Volume · Nov 12 3.16M Avg daily vol (3M) 5.09M

ABCL metrics

86 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.62
Market cap
$3.80B

Price action

23 metrics
Price change (1W)
-2.7%
Price change (30D)
-5.2%
Price change (3M)
+15.4%
Price change (6M)
+150.5%
Price change (YTD)
+249.4%
Price change (1Y)
+198.0%
Trailing year
Price change (5Y)
-20.6%
52-week high
$14.82
52-week low
$2.78
Change from 52-week high
-19.4%
Change from 52-week low
+329.9%
Annualized volatility
85.7%
Annualized volatility (3M)
81.0%
Implied volatility (30D)
95.8%
IV rank (1Y)
29.5
IV percentile (1Y)
42.9
Beta
2.6
RSI (14D)
48.2
Price vs SMA 50
-3.1%
Price vs SMA 200
+66.9%
Avg volume (3M)
5.27M
Relative volume
0.6
Average dollar volume
$63.69M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
326.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
57.5×
reciprocal yield 1.7%
P / book
3.7
reciprocal yield 27.2%
FCF yield
-0.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.8%

Historical valuation

8 metrics
P / E historical average (3Y)
14.7×
reciprocal yield 6.8%
P / E historical average (5Y)
14.7×
reciprocal yield 6.8%
EV / revenue historical average (3Y)
26.8×
reciprocal yield 3.7%
EV / revenue historical average (5Y)
26.8×
reciprocal yield 3.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-09

Profitability

9 metrics
Gross margin
—
Operating margin
-298.0%
Trailing 12 months
Net margin
-218.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$202.19M
Net income (TTM)
−$148.29M
Trailing 12 months
Diluted EPS (TTM)
$-0.48
FCF margin
-48.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.22
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.66
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.48
Operating cash flow per diluted share (TTM)
$-0.06
Free cash flow per diluted share (TTM)
$-0.11
Capital expenditures per diluted share (TTM)
$0.06
R&D per diluted share (TTM)
$0.61
Stock compensation per diluted share (TTM)
$0.16
Book value per share
$3.22

Growth

11 metrics
Revenue growth YoY
+18.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$67.86M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.4%
Year over year · more shares
Revenue CAGR (3Y)
-46.3%
Revenue CAGR (5Y)
-20.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-14.0%
Return on assets
-9.9%
Debt / equity
—
Current ratio
12.4
EBITDA (TTM)
−$222.24M
Free cash flow (TTM)
−$32.85M
Quick ratio
12.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$163.80M
Total assets
$1.50B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$15.43M
Capital expenditures (TTM)
$17.42M
R&D (TTM)
$186.28M
SG&A (TTM)
—
Stock compensation (TTM)
$48.87M
R&D / revenue
274.5%
Stock compensation / revenue
72.0%

Ownership (13F)

9 metrics
13F filers
151
13F filer change QoQ
+13
Institutional ownership
37.5%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
23.1%
Private-fund adviser ownership
22.1%
Active holders' share change QoQ
-0.7%
Holder tenure
15.3
Price vs estimated holder cost
+75.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.0%

Short interest

3 metrics
Short interest
8.9%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
$680,742
Insider-sentiment score
88 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 91 filings 83 filers Visit website Investor relations